Jyong Biotech (NASDAQ:MENS) Shares Down 5% – Time to Sell?

Jyong Biotech Ltd. (NASDAQ:MENS) shares were down 5% during mid-day trading on Wednesday . The company traded as low as $1.70 and last traded at $1.72. Approximately 210,133 shares traded hands during mid-day trading, an increase of 298% from the average daily volume of 52,794 shares. The stock had previously closed at $1.81.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jyong Biotech in a research report on Friday, May 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

Jyong Biotech Stock Performance

The company has a 50-day moving average of $2.20 and a 200-day moving average of $5.47.

Jyong Biotech (NASDAQ:MENS) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.02) EPS for the quarter.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in MENS. China Universal Asset Management Co. Ltd. bought a new position in Jyong Biotech during the 4th quarter worth $49,000. Man Group plc bought a new position in Jyong Biotech during the 4th quarter worth $56,000. BNP Paribas Financial Markets bought a new position in shares of Jyong Biotech in the third quarter worth $67,000. Millennium Management LLC increased its holdings in shares of Jyong Biotech by 209.4% during the fourth quarter. Millennium Management LLC now owns 40,258 shares of the company’s stock valued at $159,000 after purchasing an additional 27,245 shares during the period. Finally, Geode Capital Management LLC increased its holdings in shares of Jyong Biotech by 19.6% during the fourth quarter. Geode Capital Management LLC now owns 64,382 shares of the company’s stock valued at $254,000 after purchasing an additional 10,538 shares during the period.

Jyong Biotech Company Profile

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.